Presentation is loading. Please wait.

Presentation is loading. Please wait.

Morten Hoyer, Ph. D. , Henrik Roed, D. M. Sc

Published byRandi Hald Modified over 6 years ago

Similar presentations

Presentation on theme: "Morten Hoyer, Ph. D. , Henrik Roed, D. M. Sc"— Presentation transcript:

1 Prospective study on stereotactic radiotherapy of limited-stage non–small-cell lung cancer 
Morten Hoyer, Ph.D., Henrik Roed, D.M.Sc., Anders Traberg Hansen, B.S., Lars Ohlhuis, Jorgen Petersen, B.S., Hanne Nellemann, M.D., Anne Kiil Berthelsen, M.D., Cai Grau, D.M.Sc., Svend Aage Engelholm, D.M.Sc., Hans von der Maase, D.M.Sc.  International Journal of Radiation Oncology • Biology • Physics  Volume 66, Issue 4, Pages S128-S135 (November 2006) DOI: /j.ijrobp Copyright © 2006 Elsevier Inc. Terms and Conditions

2 Fig. 1 Treatment plan for stereotactic body radiotherapy of a patient with non–small-cell lung cancer. International Journal of Radiation Oncology • Biology • Physics  , S128-S135DOI: ( /j.ijrobp ) Copyright © 2006 Elsevier Inc. Terms and Conditions

3 Fig. 2 Age, lung physiology according to forced expiratory volume in 1 s (FEV-1), and tumor diameter before treatment in 40 patients with Stage I non–small-cell lung cancer treated with stereotactic body radiotherapy. International Journal of Radiation Oncology • Biology • Physics  , S128-S135DOI: ( /j.ijrobp ) Copyright © 2006 Elsevier Inc. Terms and Conditions

4 Fig. 3 Failure pattern in 16 of 40 patients with Stage 1 non–small-cell lung cancer (NSCLC) after stereotactic body radiotherapy, according to local (T), thoracic node (N), or distant failures (M). Two patients with M failure were considered as having possible new primary cancers. International Journal of Radiation Oncology • Biology • Physics  , S128-S135DOI: ( /j.ijrobp ) Copyright © 2006 Elsevier Inc. Terms and Conditions

5 Fig. 4 Local control and progression-free survival (a) and cancer-specific and overall survival (b) in 40 patients treated with stereotactic body radiotherapy. International Journal of Radiation Oncology • Biology • Physics  , S128-S135DOI: ( /j.ijrobp ) Copyright © 2006 Elsevier Inc. Terms and Conditions

6 Fig. 5 Cancer-specific survival in patients with tumor diameter ≤30 mm or >30 mm (p = 0.04). International Journal of Radiation Oncology • Biology • Physics  , S128-S135DOI: ( /j.ijrobp ) Copyright © 2006 Elsevier Inc. Terms and Conditions

7 Fig. 6 Actuarial time course of performance status (a) and lung function (b) in patients treated with stereotactic body radiotherapy. World Health Organization (WHO) performance status 2 is defined as being ambulatory and capable of all self-care but unable to carry out any work activities and in bed less than half of the day. Grade 2 pulmonary toxicity is characterized by dyspnea during exercise. International Journal of Radiation Oncology • Biology • Physics  , S128-S135DOI: ( /j.ijrobp ) Copyright © 2006 Elsevier Inc. Terms and Conditions

Download ppt "Morten Hoyer, Ph. D. , Henrik Roed, D. M. Sc"

Similar presentations

Incidence of Late Rectal and Urinary Toxicities After Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Localized Prostate.

Incidence of Late Rectal and Urinary Toxicities After Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Localized Prostate.
Curative Treatment of Stage I Non-Small-Cell Lung Cancer in Patients With Severe COPD: Stereotactic Radiotherapy Outcomes and Systematic Review  David.

Curative Treatment of Stage I Non-Small-Cell Lung Cancer in Patients With Severe COPD: Stereotactic Radiotherapy Outcomes and Systematic Review  David.
COSMIC: A Regimen of Intensity Modulated Radiation Therapy Plus Dose-Escalated, Raster-Scanned Carbon Ion Boost for Malignant Salivary Gland Tumors: Results.

COSMIC: A Regimen of Intensity Modulated Radiation Therapy Plus Dose-Escalated, Raster-Scanned Carbon Ion Boost for Malignant Salivary Gland Tumors: Results.
Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Cost-Effectiveness Analysis of Stereotactic Body Radiotherapy and Radiofrequency Ablation for Medically Inoperable, Early-Stage Non–Small Cell Lung Cancer 

Cost-Effectiveness Analysis of Stereotactic Body Radiotherapy and Radiofrequency Ablation for Medically Inoperable, Early-Stage Non–Small Cell Lung Cancer 
18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy 

18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy 
Lactate-Base 1H Magnetic Spectroscopy Does Not Predict Response and Outcomes in Patients With Stage IV Head and Neck Squamous Cell Carcinoma  Q. Le, A.

Lactate-Base 1H Magnetic Spectroscopy Does Not Predict Response and Outcomes in Patients With Stage IV Head and Neck Squamous Cell Carcinoma  Q. Le, A.
Higher Biologically Effective Dose of Radiotherapy Is Associated With Improved Outcomes for Locally Advanced Non–Small Cell Lung Carcinoma Treated With.

Higher Biologically Effective Dose of Radiotherapy Is Associated With Improved Outcomes for Locally Advanced Non–Small Cell Lung Carcinoma Treated With.
Close or Positive Margins After Mastectomy for DCIS: Pattern of Relapse and Potential Indications for Radiotherapy  Afshin Rashtian, M.D., Shawn Iganej,

Close or Positive Margins After Mastectomy for DCIS: Pattern of Relapse and Potential Indications for Radiotherapy  Afshin Rashtian, M.D., Shawn Iganej,
The impact of ipsilateral breast tumor recurrence on cause specific survival in DCIS patients treated with breast conserving therapy or mastectomy  C.

The impact of ipsilateral breast tumor recurrence on cause specific survival in DCIS patients treated with breast conserving therapy or mastectomy  C.
Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and.

Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and.
Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast.

Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast.
Higher-Than-Conventional Radiation Doses in Localized Prostate Cancer Treatment: A Meta-analysis of Randomized, Controlled Trials  Gustavo Arruda Viani,

Higher-Than-Conventional Radiation Doses in Localized Prostate Cancer Treatment: A Meta-analysis of Randomized, Controlled Trials  Gustavo Arruda Viani,
Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT)  Neal E. Dunlap,

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT)  Neal E. Dunlap,
Salvage Stereotactic Body Radiotherapy (SBRT) Following In-Field Failure of Initial SBRT for Spinal Metastases  Isabelle Thibault, MD, Mikki Campbell,

Salvage Stereotactic Body Radiotherapy (SBRT) Following In-Field Failure of Initial SBRT for Spinal Metastases  Isabelle Thibault, MD, Mikki Campbell,
Adjuvant Therapy in High-Risk Stage III Cutaneous Melanoma

Adjuvant Therapy in High-Risk Stage III Cutaneous Melanoma
Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 

One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Similar presentations

Ads by Google